Literature DB >> 10722480

Antimicrobial activities of mefloquine and a series of related compounds.

C M Kunin1, W Y Ellis.   

Abstract

Mefloquine was found to have bactericidal activity against methicillin- and fluoroquinolone-susceptible and -resistant strains of Staphylococcus aureus and Staphylococcus epidermidis and gentamicin- and vancomycin-resistant strains of Enterococcus faecalis and Enterococcus faecium. The MICs were 16 microg/ml, and the minimal bactericidal concentrations (MBCs) were 16 to 32 microg/ml. These concentrations cannot be achieved in serum. Mefloquine was active at a more achievable concentration against penicillin-susceptible and -resistant Streptococcus pneumoniae, with MICs of 0.2 to 1.5 microg/ml. Mefloquine was not active against gram-negative bacteria and yeasts. In an attempt to find more active derivatives, 400 mefloquine-related compounds were selected from the chemical inventory of The Walter Reed Army Institute of Research. We identified a series of compounds containing a piperidine methanol group attached to pyridine, quinoline, and benzylquinoline ring systems. These had activities similar to that of mefloquine against S. pneumoniae but were far more active against other gram-positive bacteria (MICs for staphylococci, 0.8 to 6.3 microg/ml). They had activities similar to that of amphotericin B against Candida spp. and Cryptococcus neoformans. Combinations of the compounds with gentamicin and vancomycin were additive against staphylococci and pneumococci. The MIC and MBC of gentamicin were decreased by four- to eightfold when this drug was combined with limiting dilutions of the compounds. There was no antagonism with other antimicrobial drugs. The compounds were rapidly bactericidal. They appear to act by disrupting cell membranes. Combinations of the compounds with aminoglycoside antibiotics may have potential for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722480      PMCID: PMC89781          DOI: 10.1128/AAC.44.4.848-852.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

2.  Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria.

Authors:  P C Mehaffey; M S Barrett; S D Putnam; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1995 Sep-Oct       Impact factor: 2.803

3.  Lack of bioequivalence of a generic mefloquine tablet with the standard product.

Authors:  E Weidekamm; G Rüsing; H Caplain; F Sörgel; C Crevoisier
Journal:  Eur J Clin Pharmacol       Date:  1998-10       Impact factor: 2.953

4.  Comparison of whole blood and serum levels of mefloquine and its carboxylic acid metabolite.

Authors:  G D Todd; A P Hopperus Buma; M D Green; C A Jaspers; H O Lobel
Journal:  Am J Trop Med Hyg       Date:  1997-10       Impact factor: 2.345

5.  The effects of mefloquine on Escherichia coli.

Authors:  R E Brown; F A Stancato; A D Wolfe
Journal:  Life Sci       Date:  1979-11-19       Impact factor: 5.037

6.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

7.  Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Authors:  L E Bermudez; P Kolonoski; M Wu; P A Aralar; C B Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

8.  In vitro susceptibility of selected non-protozoa to mefloquine.

Authors:  B J Bromke; M McGinn
Journal:  Acta Microbiol Hung       Date:  1993

9.  Quinine specifically inhibits the proteolipid subunit of the F0F1 H+ -ATPase of Streptococcus pneumoniae.

Authors:  R Muñoz; E García; A G De la Campa
Journal:  J Bacteriol       Date:  1996-04       Impact factor: 3.490

  9 in total
  15 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates.

Authors:  Marhiah C Montoya; Sarah Beattie; Kathryn M Alden; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.

Authors:  Elamparithi Jayamani; Nagendran Tharmalingam; Rajmohan Rajamuthiah; Jeffrey J Coleman; Wooseong Kim; Ikechukwu Okoli; Ana M Hernandez; Kiho Lee; Gerard J Nau; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae.

Authors:  Antonio Javier Martín-Galiano; Begoña Gorgojo; Calvin M Kunin; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  An image-based 384-well high-throughput screening method for the discovery of biofilm inhibitors in Vibrio cholerae.

Authors:  Kelly C Peach; Walter M Bray; Nicholas J Shikuma; Nadine C Gassner; R Scott Lokey; Fitnat H Yildiz; Roger G Linington
Journal:  Mol Biosyst       Date:  2011-01-18

Review 6.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

7.  Discovery of a Novel Dibromoquinoline Compound Exhibiting Potent Antifungal and Antivirulence Activity That Targets Metal Ion Homeostasis.

Authors:  Haroon Mohammad; Nehal H Elghazawy; Hassan E Eldesouky; Youssef A Hegazy; Waleed Younis; Larisa Avrimova; Tony Hazbun; Reem K Arafa; Mohamed N Seleem
Journal:  ACS Infect Dis       Date:  2018-02-02       Impact factor: 5.084

8.  The Human Gut Microbiome as a Transporter of Antibiotic Resistance Genes between Continents.

Authors:  Johan Bengtsson-Palme; Martin Angelin; Mikael Huss; Sanela Kjellqvist; Erik Kristiansson; Helena Palmgren; D G Joakim Larsson; Anders Johansson
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

9.  Genetic characterization of optochin-susceptible viridans group streptococci.

Authors:  Antonio J Martín-Galiano; Luz Balsalobre; Asunción Fenoll; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).

Authors:  Christopher M Russo; Arijit A Adhikari; Daniel R Wallach; Sandra Fernandes; Amanda N Balch; William G Kerr; John D Chisholm
Journal:  Bioorg Med Chem Lett       Date:  2015-09-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.